Aspirin suppresses hepatocellular carcinoma progression by inhibiting platelet activity

Figure 6 Aspirin can inhibit the progression of hepatocellular carcinoma by inhibiting platelets. A: Routine blood was used to detect the platelet content in the whole blood of mice in different treatment groups, and statistical analysis was performed; B-D: Blood biochemistry was used to detect alanine transaminase, aspartate transaminase, and albumin in the anticoagulated plasma of mice in different treatment groups, and statistical analysis was performed; E: Macroscopic map of liver tissue from hepatocellular carcinoma mice in different treatment groups; F: Immunohistochemistry was used to detect the content of Ki67 (antigen identified by monoclonal antibody Ki67) in liver tissues from the different treatment groups; G and H: In vivo experiments were performed to detect the effect of aspirin on tumor growth, and statistical analysis was performed. The figure shows the mean ± SD of the experimental results, with asterisks denoting significant differences between the two groups (^aP < 0.05, ^bP < 0.01, ^cP < 0.001). NC: Negative control; WT: Wild-type; PLT: Platelets; HCC: Hepatocellular carcinoma; ALT: Alanine transaminase; AST: Aspartate transaminase; ALB: Albumin.